Sign in →

Test ID IGFMS Insulin-Like Growth Factor-1, Mass Spectrometry, Serum

Useful For

Evaluation of growth disorders


Evaluation of growth hormone deficiency or excess in children and adults


Monitoring of recombinant human growth hormone treatment


Follow-up of individuals with acromegaly and gigantism

Method Name

Liquid Chromatography-Mass Spectrometry (LC/MS)

Reporting Name


Specimen Type


Necessary Information

Indicate patient's age and sex.

Specimen Required


Preferred: Red top

Acceptable: Serum gel

Specimen Volume: 0.5 mL

Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Frozen (preferred) 28 days
  Ambient  72 hours
  Refrigerated  72 hours

Clinical Information

Insulin-like growth factor 1 (IGF1) is a 70-amino acid polypeptide (molecular weight 7649 Da; Uniprot Accession P05019 [aa 49-118]). IGF1 is a member of a family of closely related growth factors with high homology to insulin that signal through a corresponding group of highly homologous tyrosine kinase receptors. IGF1 is produced by many tissues, but the liver is the main source of circulating IGF1. IGF1 is the major mediator of the anabolic and growth-promoting effects of growth hormone (GH). IGF1 is transported by IGF-binding proteins, in particular insulin-like growth factor-binding protein 3 (IGFBP3), which also controls its bioavailability and half-life. Noncomplexed IGF1 and IGFBP3 have short half-lives (t1/2) of 10 and 30 to 90 minutes, respectively, while the IGFBP3/IGF1 complex is cleared with a much slower t1/2 of 12 hours.


The secretion patterns of IGF1 and IGFBP3 mimic each other, their respective syntheses being controlled by GH. Unlike GH secretion, which is pulsatile and demonstrates significant diurnal variation, IGF1 and IGFBP3 levels show only minor fluctuations. IGF1 and IGFBP3 serum levels, therefore, represent a stable and integrated measurement of GH production and tissue effect.


Low IGF1 and IGFBP3 levels are observed in GH deficiency or GH resistance. If acquired in childhood, these conditions result in short stature.


Childhood GH deficiency can be an isolated abnormality or associated with deficiencies of other pituitary hormones. Some of the latter cases may be due to pituitary or hypothalamic tumors, or result from cranial radiation or intrathecal chemotherapy for childhood malignancies.


Most GH resistance in childhood is mild-to-moderate, with causes ranging from poor nutrition to severe systemic illness (eg, renal failure). These individuals may have IGF1 and IGFBP3 levels within the reference range. Severe childhood GH resistance is rare and usually due to defects of the GH-receptor, its downstream signaling cascades, or deleterious mutations in IGF1, its binding proteins, or its receptor signaling cascades.


Both GH deficiency and mild-to-moderate GH resistance can be treated with recombinant human GH (rhGH) injections, while severe resistance will usually not respond to GH. However, such patients might respond to recombinant IGF1 therapy, unless the underlying defect is in the IGF1 receptor or its downstream signaling systems.


The exact prevalence and causes of adult GH resistance are uncertain, but adult GH deficiency is seen mainly in pituitary tumor patients. It is associated with decreased muscle bulk and increased cardiovascular morbidity and mortality, but replacement therapy remains controversial.


Elevated serum IGF1 and IGFBP3 levels often indicate a sustained overproduction of GH, or excessive rhGH therapy. Endogenous GH excess is caused mostly by GH-secreting pituitary adenomas, resulting in gigantism, if acquired before epiphyseal closure, and in acromegaly thereafter. Both conditions are associated with generalized organomegaly, hypertension, diabetes, cardiomyopathy, osteoarthritis, compression neuropathies, a mild increase in cancer risk (breast, colon, prostate, lung), and diminished longevity. It is plausible, but unproven, that long-term rhGH overtreatment may result in similar adverse outcomes.


Malnutrition results in low serum IGF1 concentrations, which recover with restoration of adequate nutrition.

Reference Values


0-11 months: 18-156 ng/mL

1 year: 14-203 ng/mL

2 years: 16-222 ng/mL

3 years: 22-229 ng/mL

4 years: 30-236 ng/mL

5 years: 39-250 ng/mL

6 years: 47-275 ng/mL

7 years: 54-312 ng/mL

8 years: 61-356 ng/mL

9 years: 67-405 ng/mL

10 years: 73-456 ng/mL

11 years: 79-506 ng/mL

12 years: 84-551 ng/mL

13 years: 90-589 ng/mL

14 years: 95-618 ng/mL

15 years: 99-633 ng/mL

16 years: 104-633 ng/mL

17 years: 107-615 ng/mL

18-22 years: 91-442 ng/mL

23-25 years: 66-346 ng/mL

26-30 years: 60-329 ng/mL

31-35 years: 54-310 ng/mL

36-40 years: 48-292 ng/mL

41-45 years: 44-275 ng/mL

46-50 years: 40-259 ng/mL

51-55 years: 37-245 ng/mL

56-60 years: 34-232 ng/mL

61-65 years: 33-220 ng/mL

66-70 years: 32-209 ng/mL

71-75 years: 32-200 ng/mL

76-80 years: 33-192 ng/mL

81-85 years: 33-185 ng/mL

86-90 years: 33-179 ng/mL

≥91 years: 32-173 ng/mL



0-11 months: 14-192 ng/mL

1 year: 23-243 ng/mL

2 years: 28-256 ng/mL

3 years: 31-249 ng/mL

4 years: 33-237 ng/mL

5 years: 36-234 ng/mL

6 years: 39-246 ng/mL

7 years: 44-279 ng/mL

8 years: 51-334 ng/mL

9 years: 61-408 ng/mL

10 years: 73-495 ng/mL

11 years: 88-585 ng/mL

12 years: 104-665 ng/mL

13 years: 120-719 ng/mL

14 years: 136-729 ng/mL

15 years: 147-691 ng/mL

16 years: 153-611 ng/mL

17 years: 149-509 ng/mL

18-22 years: 85-370 ng/mL

23-25 years: 73-320 ng/mL

26-30 years: 66-303 ng/mL

31-35 years: 59-279 ng/mL

36-40 years: 54-258 ng/mL

41-45 years: 49-240 ng/mL

46-50 years: 44-227 ng/mL

51-55 years: 40-217 ng/mL

56-60 years: 37-208 ng/mL

61-65 years: 35-201 ng/mL

66-70 years: 34-194 ng/mL

71-75 years: 34-187 ng/mL

76-80 years: 34-182 ng/mL

81-85 years: 34-177 ng/mL

86-90 years: 33-175 ng/mL

≥91 years: 25-179 ng/mL


Tanner Stage reference ranges:


Stage I: 81-255 ng/mL

Stage II: 106-432 ng/mL

Stage III: 245-511 ng/mL

Stage IV: 223-578 ng/mL

Stage V: 227-518 ng/mL



Stage I: 86-323 ng/mL

Stage II: 118-451 ng/mL

Stage III: 258-529 ng/mL

Stage IV: 224-586 ng/mL

Stage V: 188-512 ng/mL


Tanner Stage reference source: Bindlingmaier M, Friedrich N, Emeny RT,et al: Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014 May;99(5):1712-1721


Note: Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for boys at a median age of 11.5 (±2) years and for girls at a median age of 10.5 (±2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African American girls. For boys, there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage V (young adult) should be reached by age 18.


Both insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 (IGFBP3) measurements can be used to assess growth hormone (GH) excess or deficiency. However, for all applications, IGF1 measurement has generally been shown to have superior diagnostic sensitivity and specificity, and should be used as the primary test. In particular, in the diagnosis and follow-up of acromegaly and gigantism, IGFBP3 measurement adds little if anything to IGF1 testing.


The combination of IGF1 and IGFBP3 measurements might offer some benefits over either analyte alone in the diagnosis of GH deficiency and resistance, and in the monitoring of recombinant human GH (rhGH) therapy.


Serum IGF1 and IGFBP3 concentrations below the 2.5th percentile (Standard deviation score, Z-score of <-2) for age are consistent with GH deficiency or severe GH resistance, but patients with incomplete GH deficiency or mild-to-moderate GH resistance may have levels within the reference range. In GH deficiency, GH levels may also be low and can show suboptimal responses in stimulation tests (eg, exercise, clonidine, arginine, ghrelin, growth hormone-releasing hormone, insulin-induced hypoglycemia), while in severe GH resistance, GH levels might be substantially elevated. However, dynamic GH testing is not always necessary for diagnosis. If it is undertaken, it should be performed and interpreted in endocrine testing centers under the supervision of a pediatric or adult endocrinologist.


The aim of both pediatric and adult GH replacement therapy is to achieve IGF1 and IGFBP3 levels within the reference range, ideally within the middle-to-upper third. Higher levels are rarely associated with any further therapeutic gains, but could potentially lead to long-term problems of GH excess.


Elevated IGF1 and IGFBP3 levels support the diagnosis of acromegaly or gigantism in individuals with appropriate symptoms or signs. In successfully treated patients, both levels should be within the normal range, ideally within the lower third. In both diagnosis and follow-up, IGF1 levels correlate better with clinical disease activity than IGFBP3 levels.


After transsphenoidal removal of pituitary tumors in patients with acromegaly, IGF-I concentration starts to decrease and returns to normal levels in most patients postoperatively by the fourth day.


Persons with anorexia or malnutrition have low values of IGF1. IGF1 is a more sensitive indicator than prealbumin, retinol-binding protein, or transferrin for monitoring nutritional repletion.

Clinical Reference

1. Wetterau L, Cohen P: Role of insulin-like growth factor monitoring in optimizing growth hormone therapy. J Ped Endocrinol Metab. 2000;13 Suppl 6:1371-1376. doi: 10.1515/jpem-2000-s610

2. Granada ML, Murillo J, Lucas A, et al: Diagnostic efficiency of serum IGF-1, IGF-binding protein-3 (IGFBP-3), IGF/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population. Eur J Endocrinol. 2000 Mar;142(3):243-253. doi: 10.1530/eje.0.1420243

3. Boquete HR, Sobrado PGV, Fideleff HL, et al: Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-1 and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J Endocrinol Metab. 2003 Oct;88(10):4702-4708. doi: 10.1210/jc.2003-030412

4. Brabant G: Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol. 2003 Apr;148 Suppl 2:S15-S20. doi: 10.1530/eje.0.148s015

5. Bidlingmaier M, Friedrich N, Emeny RT, et,al: Reference intervals for insulin-like growth factor-1 (IGF-1) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-1 immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014 May;99(5):1712-1721. doi: 10.1210/jc.2013-3059

Day(s) Performed

Monday through Friday, Sunday

Report Available

2 to 3 days

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
IGFMS IGF-1, LC/MS, S 2484-4


Result ID Test Result Name Result LOINC Value
62750 IGF-1, LC/MS, S 2484-4
35781 Z-score 73561-3


If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.